ROBERT EDWARD DEMPSKI
Pharmacy in Dresher, PA
License number
Pennsylvania RP022679L
Category
Pharmacy
Type
Pharmacist
Address
Address
Dresher, PA 19025
Professional information
Controlled Release Combination Of Carbidopa/Levodopa
US Patent:
4983400, Jan 8, 1991
Filed:
Dec 1, 1989
Appl. No.:
7/444222
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 922, A61K 926, A61K 3178
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.
Sustained Release Indomethacin
US Patent:
4173626, Nov 6, 1979
Filed:
Dec 11, 1978
Appl. No.:
5/968608
Inventors:
Robert E. Dempski - Dresher PA
Gunvant N. Mehta - Lansdale PA
Joseph C. Saboe - Norristown PA
Gunvant N. Mehta - Lansdale PA
Joseph C. Saboe - Norristown PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 922, A61K 948
US Classification:
424 19
Abstract:
A sustained release indomethacin pharmaceutical product is provided that utilizes a pellet formulation encapsulated in a hard gelatin capsule. A portion of the pellets is uncoated for immediate and rapid release of indomethacin for elevating the plasma level. The remainder of the pellets are coated with a polymer to sustain the plasma level. The uncoated and coated pellets may be mixed with non-medicated pellets as a capsule filler.
Controlled Release Combination Of Carbidopa/Levodopa
US Patent:
4832957, May 23, 1989
Filed:
Jul 25, 1988
Appl. No.:
7/223861
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 920, A61K 922, A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.
Controlled Release Combination Of Carbidopa/Levodopa
US Patent:
4900755, Feb 13, 1990
Filed:
Feb 24, 1989
Appl. No.:
7/315057
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co. - Rahway NJ
International Classification:
A61K 920, A61K 922, A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.
Methyldopa Composition
US Patent:
4404193, Sep 13, 1983
Filed:
Oct 9, 1981
Appl. No.:
6/309956
Inventors:
Robert E. Dempski - Dresher PA
Joseph L. O'Neill - Lansdale PA
Joseph L. O'Neill - Lansdale PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 31195, A61K 31715
US Classification:
424176
Abstract:
An aqueous suspension containing methyldopa and sucrose is disclosed. This composition is an oral dosage form for treating hypertension that is bioavailable.